Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. (Q41272702)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 April 2015

Language	Label	Description	Also known as
English	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.	scientific article published on 27 April 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

B-cell non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

René-Olivier Casasnovas

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ranjana H. Advani

10

object named as

Ranjana Advani

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Maria Corinna A Palanca-Wessels

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Myron Czuczman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Gilles Salles

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sarit Assouline

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Laurie H Sehn

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Manish R Patel

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Randeep Sangha

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Anton Hagenbeek

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Herve Tilly

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sreeni Yalamanchili

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Robert Kahn

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Randall C Dere

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Dan Lu

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Surai Jones

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Cheryl Jones

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yu-Waye Chu

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Franck Morschhauser

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

27 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

704-715

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapsed/refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970128-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70128-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25925619%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41272702&oldid=2095778040"